• The FDA approved Alvotech's new manufacturing process for Simlandi, its biosimilar to Humira.
• The process more than doubles drug substance output per batch at its Reykjavik facility without increasing upstream manufacturing scale.
• Producing the same quantity in fewer batches frees capacity for other biosimilars while maintaining product quality, safety and efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006704), on October 20, 2026, and is solely responsible for the information contained therein.